Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been assigned a consensus rating of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $5.02.

Several equities research analysts recently commented on the company. HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a research report on Friday. Wedbush reaffirmed an “outperform” rating and set a $5.00 price objective on shares of CytomX Therapeutics in a research report on Friday.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CTMX. US Bancorp DE purchased a new stake in shares of CytomX Therapeutics during the 3rd quarter valued at about $40,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of CytomX Therapeutics by 10.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock worth $331,000 after purchasing an additional 26,373 shares during the last quarter. FMR LLC increased its position in shares of CytomX Therapeutics by 17.3% during the third quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock worth $335,000 after acquiring an additional 41,949 shares during the period. Jacobs Levy Equity Management Inc. raised its position in CytomX Therapeutics by 1.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 16,359 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of CytomX Therapeutics by 4.4% in the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock valued at $948,000 after acquiring an additional 34,032 shares in the last quarter. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Price Performance

Shares of NASDAQ:CTMX opened at $0.66 on Wednesday. The business has a fifty day moving average price of $0.84 and a 200-day moving average price of $1.02. The company has a market capitalization of $52.03 million, a PE ratio of 3.91 and a beta of 1.01. CytomX Therapeutics has a 1-year low of $0.60 and a 1-year high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.45. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The business had revenue of $38.09 million during the quarter, compared to analysts’ expectations of $13.53 million. On average, sell-side analysts anticipate that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.